



Acute kidney injury following multisystem inflammatory syndrome associated with SARS-CoV-2 infection in children: a systematic review and meta-analysis

Anchal Kumar Tripathi¹ · Rakesh Kumar Pilania² · Girish Chandra Bhatt¹ · Mahendra Atlani³ · Amber Kumar¹ · Shikha Malik¹

Received: 24 April 2022 / Revised: 19 July 2022 / Accepted: 20 July 2022

This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply 2022

Abstract

Introduction Multisystem inflammatory syndrome (MIS-C) is a rare paediatric hyper-inflammatory disorder that occurs following SARS-CoV-2 infection. Acute kidney injury (AKI) occurs in approximately one-quarter to one-third of the patients with MIS-C and is associated with poor prognosis in critically ill children. This systematic review is aimed to evaluate the incidence of AKI, mortality, and the need for kidney replacement therapy (KRT) in patients with MIS-C.

Methods We searched databases from Medline, EMBASE, Cochrane Register, and Google Scholar from December 2019 to December 2021 with our search strategy. Studies meeting the following criteria were included in this systematic review: (1) articles on AKI in MIS-C; (2) studies providing AKI in MIS-C and COVID-19 infection separately; (3) studies reporting outcomes such as mortality, KRT, serum creatinine; length of hospital/ICU stay.

Quality assessment The quality of the included studies was independently assessed by using the National Heart Lung and Blood Institute (NHLBI) quality assessment tool for cohort studies and case series.

Statistical analysis Outcomes and their 95% confidence intervals (CI) were reported if a meta-analysis of these outcomes was conducted. Heterogeneity was reported using I^2 statistics, and heterogeneity $\geq 50\%$ was considered high. We used Baujat's plot for the contribution of each study toward overall heterogeneity. In sensitivity analysis, the summary estimates were assessed by repeating meta-analysis after omitting one study at a time. Forest plots were used for reporting outcomes in each study and with their 95% CI. All statistical tests were performed using R software version 4.0.3.

Results A total of 24 studies were included in this systematic review and of these, 11 were included in the meta-analysis. The pooled proportion of patients with MIS-C developing AKI was 20% (95% CI: 14–28%, $I^2 = 80\%$). Pooled proportion of death in children with MIS-C was 4% (95% CI: 1–14%; $I^2 = 93\%$). The odds of death in patients with AKI were 4.68 times higher than in patients without AKI (95% CI: 1.06–20.7%; $I^2 = 17\%$). The overall pooled proportion of MIS-C-induced AKI patients requiring KRT was 15% (95% CI: 4–42%; $I^2 = 91\%$).

Conclusion Approximately one-fifth of children with MIS-C develop AKI which is associated with higher odds of death. PROSPERO registration: CRD42022306170

Keywords Multisystem inflammatory syndrome in children (MIS-C) · Acute kidney injury (AKI) · Meta-analysis

✉ Girish Chandra Bhatt
drgecbhatt@gmail.com

¹ Department of Pediatrics, ISN-SRC, All India Institute of Medical Sciences (AIIMS), Room no 1023, Academic Block, Saket Nagar, Bhopal, MP 462024, India

² Advanced Pediatrics Centre, Division of Clinical Immunology and Rheumatology, Post Graduate Institute of Medical Sciences (PGI), Chandigarh, India

³ Department of Nephrology, All India Institute of Medical Sciences (AIIMS), Bhopal, MP, India

Introduction

Severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection is typically characterized by lower respiratory tract involvement that leads to acute respiratory distress syndrome in patients with moderate to severe COVID-19 disease. Multisystem inflammatory syndrome (MIS-C) is a rare paediatric hyper-inflammatory disorder following SARS-CoV-2 infection that manifests as fever, gastrointestinal symptoms, cardiac dysfunction, and shock [1, 2].

Incidence of MIS-C is nearly 3.16 cases per 10,000 SARS-CoV-2-infected persons [3]. Different scientific societies, like the Centers for Disease Control (CDC), World Health Organization (WHO), and Royal College of Paediatric and Child Health (RCPCH), have proposed diagnostic criteria [4–6]. MIS-C is thought to result from infection-related autoimmunity [7]. Reports from different parts of the world have shown an overlapping clinical picture of MIS-C with incomplete Kawasaki disease or toxic shock syndrome (TSS) [8] and multisystem involvement, including acute kidney injury (AKI) [9].

AKI occurs in approximately 25 to 33% of the patients with MIS-C [10, 11] and is associated with poor prognosis in critically ill children [10]. The mechanism of AKI in SARS-CoV-2 patients is multifactorial, including dehydration, poor cardiac output, cytokine storm, the direct cytopathic effect of the virus on renal tubular cells, and the use of nephrotoxic drugs. However, the mechanism implicated in AKI development in MIS-C patients is chiefly due to renal hypoperfusion [11, 12].

There is a lack of data on AKI incidence, its effect on mortality, and the requirement of kidney replacement therapy (KRT) in children with MIS-C [10, 11, 13]. This systematic review is aimed to evaluate the incidence of AKI, mortality, and the need for KRT in patients with MIS-C.

Methods

Data sources

We searched databases from Medline, EMBASE, Cochrane Register, and Google Scholar from December 2019 to December 2021. The following search strategy was used for the extraction of data ‘((((((acute kidney injury) OR (acute renal failure)) OR (renal failure)) AND (multisystem inflammatory syndrome)) OR (MIS-C)) OR (pediatric multisystem inflammatory syndrome)) OR (PIMS covid)’.

Inclusion criterion

Studies meeting the following criteria were included in this systematic review: (1) articles on AKI in MIS-C; (2) studies providing AKI in MIS-C and COVID-19 infection separately; (3) studies reporting outcomes such as mortality, KRT, serum creatinine; length of hospital/ICU stay. Studies were excluded if they were case reports, case series with the inclusion of < 10 patients, review articles, letters, or commentaries.

Data extraction

Two authors (AT and RKP) independently reviewed the literature, title, abstract, and full-text article. Any disagreement

during the data extraction was resolved by discussing with the third author (GCB). Data related to AKI incidence, overall mortality, the need for KRT, and length of hospital stay were calculated.

Quality assessment

The quality of the included studies was independently assessed by two authors (RKP, AK) using the National Heart Lung and Blood Institute (NHLBI) quality assessment tool for cohort studies and case series. Any disagreement was resolved by consulting with a third author (GCB).


Statistical analysis

The systematic review was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA). Outcomes and their 95% confidence intervals (CI) were reported if a meta-analysis of these outcomes was conducted. Heterogeneity was reported using I^2 statistics, and heterogeneity $\geq 50\%$ was considered high. In case of high heterogeneity, the random-effects model was used. We used Baujat’s plot for the contribution of each study toward overall heterogeneity [14]. In sensitivity analysis, the summary estimates were assessed by repeating meta-analysis after omitting one study at a time. The influence of an individual study on overall results was identified by using various statistical tests, including studentized residuals, difference in fits (DFFITS), Cooks distance, covariance ratio, tau square, and the contribution of each study in the Q, H2 test statistics value and the weights assigned to these studies [15]. Forest plots were used for reporting outcomes in each study with their 95% CI. All statistical tests were performed using R software version 4.0.3 and Revan 5.4.

Results

The search strategy yielded 5848 records. After removing duplicates, 3197 records were screened. After reading the title and abstract, 2943 were excluded. After going through the full text of 254 studies, 230 records were excluded due to the following reasons: case reports ($n = 107$), studies did not mention AKI ($n = 88$), case series with less than 10 cases ($n = 17$), and miscellaneous ($n = 18$). Finally, 24 studies were included in the systematic review — of these, 11 were included in the meta-analysis (Fig. 1). Multiple single-centre and multicentric studies published during the time period were considered for this meta-analysis, and there was a considerable overlap of data. To avoid duplication of data, we only included the nationwide multicentric studies which had collected data from single-centre studies, after confirming with the respective authors.

Fig. 1 PRISMA flow diagram describing the inclusion of studies



A total of 24 studies with 6186 children were included in the systematic review, and of these, 11 studies with 4947 children were included in the meta-analysis. Fourteen of these studies were multicentric [10, 11, 16–27], and 10 were single-centre studies [12, 28–36]. Twelve studies were conducted in the USA [10, 12, 16, 21, 23, 24, 27–29, 31, 32, 36], 2 in the UK [11, 19], 2 in Spain [18, 20], and 1 each in Columbia, Brazil, and Pakistan, respectively [17, 22, 25]. Three studies were conducted in India [30, 33, 35], and 2 were conducted in Turkey [26, 34]. Fourteen studies were retrospective [10, 16, 21, 22, 24, 26–29, 31, 32, 34–36], 7 were prospective [11, 12, 17–20, 33], while 3 were prospective as well as retrospective [23, 25, 30]. Study characteristics are described in Table 1. A total of 11 studies were included in meta-analysis. The detailed qualitative analysis of the studies is provided in Supplementary Table 1 and Supplementary Table 2.

The overall proportion of MIS-C children developing AKI

All studies reported the proportion of the children developing AKI. The pooled proportion of patients with MIS-C developing AKI was 20% (95% CI: 14–28%, $I^2 = 80\%$) (Fig. 2) (11 studies, 4947 patients). As there was unexplained heterogeneity, we used the Baujat plot and identified 2 studies (Deep A and Miller AD) [11, 27] as outliers (Supplementary Fig. 1). However, no study was found to significantly influence the heterogeneity (Supplementary Fig. 2) on performing influential analysis. Visual inspection of the funnel plot for publication bias was symmetrical, and Egger's test was non-significant ($p = 0.62$) (Supplementary Fig. 3). A subgroup analysis was done for incidence of AKI based on sample size, geography, definition of AKI used (KDIGO versus others), and multicentric versus single-centre studies. Incidence of AKI in MIS-C

Table 1 Characteristics of included studies

S. no.	Study title	Study author	Country	Multicentric/ single centre	Prospective/retrospec- tive	Median age/sample size/invasive mechani- cal ventilation (IMV)/ shock	IVIG/steroids/anti- platelet/anticoagu- lants	AKI/KRT/mortality	Study quality (NHLBI tool)
1	COVID-19-associated multisystem inflammatory syndrome in children — United States, March–July 2020	Godfred-Cato S et al. [16]	USA	Multicentric	Retrospective	Median age: 8 years Sample size: 570 IMV: 69 Shock: 202 Anticoagulants: 233	IVIG: 424 Steroids: 331 Antiplatelet drugs: 309	AKI: 105 KRT: 2 Mortality: 10	Fair
2	Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children	Lee PY et al. [28]	USA	Single centre	Retrospective	Median age: 9 years Sample size: 28 IMV: 0 Shock: 15	IVIG: 20 Steroids: 17 Antiplatelet drugs: 19 Anticoagulants: 18	AKI: 6 KRT: not mentioned Mortality: 0	Fair
3	Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in paediatric intensive care units in Spain	García-Salido A et al. [18]	Spain	Multicentric	Prospective	Median age: 9.4 years Sample size: 74 IMV: 6 Shock: 38	IVIG: 23 Steroids: 36 Antiplatelet drugs: not mentioned Anticoagulants: not mentioned	AKI: 9 KRT: 0 Mortality: 0	Good
4	Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study	Davies P et al. [19]	UK	Multicentric	Prospective	Median age: 11 years Sample size: 78 IMV: 36 Shock: 68	IVIG: 59 Steroids: 57 Antiplatelet drugs: 45 Anticoagulants: 45	No mention of AKI, but 1 patient received KRT Mortality: 2	Low

Table 1 (continued)

S. no.	Study title	Study author	Country	Multicentric/ single centre	Prospective/retrospec- tive	Median age/sample size/invasive mechani- cal ventilation (IMV)/ shock	IVIg/steroids/anti- platelet/anticoagu- lants	AKI/KRT/mortality	Study quality (NHLBI tool)
5	Acute kidney injury in pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome Coronavirus-2 pandemic: experience from PICUs across United Kingdom	Deep A et al. [11]	UK	Multicentric	Prospective	Median age: 11 years Sample size: 116 IMV: 41 Shock: 71	Not mentioned	AKI: 48 KRT: 3 Mortality: 2	Good
6	Imaging findings in multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease (COVID-19)	Blumfield E et al. [29]	USA	Single centre	Retrospective	Mean age: 9.2 years Sample size: 16 IMV: 1 Shock: 10	IVIg: 5 Steroids: 10 Antiplatelet drugs: not mentioned Anticoagulants: not mentioned	AKI: 5 KRT: not mentioned Mortality: 0	Low
7	Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations	Diorio C et al. [12]	USA	Single centre	Prospective	Median age: 9 years Sample size: 55 IMV: 4 Shock: Not mentioned (tonotropic support in 20 cases)	Not mentioned	AKI: 5 KRT: 0 Mortality: 0	Fair
8	Epidemiological and clinical profile of pediatric inflammatory multisystem syndrome —temporally associated with SARS-CoV-2 (PIMS-TS) in Indian children	Dhanalakshmi K et al. [39]	India	Single centre	Prospective and retrospec- tive	Median age: 6 years Sample size: 19 IMV: 0 Shock: 10	IVIg: 15 Steroids: 11 Antiplatelet drugs: 16 Anticoagulants: not mentioned	AKI: 3 KRT: not mentioned Mortality: 0	Low

Table 1 (continued)

S. no.	Study title	Study author	Country	Multicentric/ single centre	Prospective/retrospec- tive	Median age/sample size/invasive mechani- cal ventilation (IMV)/ shock	IVIg/steroids/anti- platelet/anticoagu- lants	AKI/KRT/mortality	Study quality (NHLBI tool)
9	Multi-inflammatory syndrome in children related to severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) in Spain	Moraleda C et al. [20]	Spain	Multicentric	Prospective	Median age: 7.6 years Sample size: 31 IMV: 6 Shock: 15	IVIg: 20 Steroids: 21 Antiplatelet drugs: not mentioned Anticoagulants: not mentioned	AKI: 4 KRT: not mentioned Mortality: 1	Good
10	Multisystem inflam- matory syndrome in children associated with novel corona- virus SARS-CoV-2; presentations to a pediatric emergency department in Michigan	Sethuraman U et al. [31]	USA	Single centre	Retrospective	Median age: 6 years Sample size: 34 IMV: 8 Shock: 13	IVIg: 34 Steroids: 0 Antiplatelet drugs: 34 Anticoagulants: 0	AKI: 10 KRT: not mentioned Mortality: 0	Fair
11	Acute hepatitis is a prominent presenta- tion of the multisys- tem inflammatory syndrome in chil- dren: a single-center report	Cantor A et al. [32]	USA	Single centre	Retrospective	Median age: not provided Sample size: 44 IMV: 1 Shock: 22	Not mentioned	AKI: 7 KRT: 1 Mortality: 0	Fair
12	Multisystem inflam- matory syndrome in children: clinical features and man- agement-intensive care experience from a pediatric public hospital in Western India	Shobhavat L et al. [33]	India	Single centre	Prospective	Median age: 7 years Sample size: 21 IMV: 7 Shock: 20	IVIg: 11 Steroids: 18 Antiplatelet drugs: not mentioned Anticoagulants: 21	AKI: 8 KRT: not mentioned Mortality: 3	Low

Table 1 (continued)

S. no.	Study title	Study author	Country	Multicentric/ single centre	Prospective/retrospec- tive	Median age/sample size/invasive mechani- cal ventilation (IMV)/ shock	IVIg/steroids/anti- platelet/anticoagu- lants	AKI/KRT/mortality	Study quality (NHLBI tool)
13	Acute kidney injury in pediatric patients hospitalized with acute COVID-19 and multisystem inflammatory syndrome in children associated with COVID-19	Basalely A et al. [10]	USA	Multicentric	Retrospective	Median age: 7.5 years Sample size: 152 IMV: 1 Shock: not mentioned (25 patients received inotropic/vasopres- sor support)	IVIg: 40 Steroids: 26 Antiplatelet drugs: not mentioned Anticoagulants: not mentioned	AKI: 10 KRT: 0 Mortality: 0	Fair
14	Clinical features and outcome of MIS-C patients: an experience from Central Anatolia	Alkan G et al. [34]	Turkey	Single centre	Retrospective	Median age: 94.5 months Sample size: 36 IMV: not mentioned Shock: 11	IVIg: 36 Steroids: 36 Antiplatelet drugs: 36 Anticoagulants: 36	AKI: 5 KRT: not mentioned Mortality: 0	Fair
15	Unusual clinical manifestations and outcome of multisystem inflammatory syndrome in children (MIS-C) in a tertiary care hospital of North India	Gupta Deh S et al. [35]	India	Single centre	Retrospective	Median age: not provided Sample size: 41 IMV: 13 Shock: 13	IVIg: 0 Steroids: 16 Antiplatelet drugs: not mentioned Anticoagulants: not mentioned	AKI: 6 KRT: not mentioned Mortality: 13	Low
16	Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort study	Lima-Setta F et al. [17]	Brazil	Multicentric	Prospective	Median age: 6.2 years Sample size: 56 IMV: 6 Shock: 33	IVIg: 50 Steroids: 31 Antiplatelet drugs: 25 Anticoagulants: 29	AKI: 5 KRT: not mentioned Mortality: 1	Fair
17	Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 Infection	Capone CA et al. [21]	USA	Multicentric	Retrospective	Median age: 8.6 years Sample size: 33 IMV: 6 Shock: 25	IVIg: 33 Steroids: 23 Antiplatelet drugs: 29 Anticoagulants: 14	AKI: 23 KRT: not mentioned Mortality: 0	Fair

Table 1 (continued)

S. no.	Study title	Study author	Country	Multicentric/ single centre	Prospective/retrospec- tive	Median age/sample size/invasive mechani- cal ventilation (IMV)/ shock	IVIG/steroids/anti- platelet/anticoagu- lants	AKI/KRT/mortality	Study quality (NHLBI tool)
18	Multisystem inflam- matory syndrome in U.S. children and adolescents	Feldstein LR et al. [23]	USA	Multicentric	Prospective and retro- spective	Median age: 8.3 years Sample size: 186 IMV: 37 Shock: not mentioned (90 patients received vasopressor support)	IVIG: 144 Steroids: 91 Antiplatelet drugs: not mentioned Anticoagulants: 87	AKI: 10 KRT: not mentioned Mortality: 4	Low
19	Kawasaki disease- like features in 10 pediatric COVID-19 cases: a retrospec- tive study	Falah NU et al. [22]	Pakistan	Multicentric	Retrospective	Mean age: 6 years Sample size: 10 IMV: 0 Shock: 6	IVIG: 9 Steroids: 3 Antiplatelet drugs: 7 Anticoagulants: not mentioned	AKI: 1 KRT: not mentioned Mortality: 0	Fair
20	Multisystem inflam- matory syndrome in children in New York State	Dufort EM et al. [24]	USA	Multicentric	Prospective	Median age: not provided Sample size: 99 IMV: 10 Shock: 10	IVIG: 69 Steroids: 63 Antiplatelet drugs: not mentioned Anticoagulants: not mentioned	AKI: 10 KRT: not mentioned Mortality: 2	Low
21	Acute kidney injury in COVID-19-asso- ciated multisystem inflammatory syn- drome in children (MIS-C)	Marissa Lipton et al. [36]	USA	Single centre	Retrospective	Median age: 7 years Sample size: 57 IMV: 1 Shock: not mentioned (18 patients received vasopressors)	IVIG: 21 Steroids: 26 Antiplatelet drugs: not mentioned Anticoagulants: not mentioned	AKI: 26 KRT: 1 Mortality: 0	Good
22	Mortality and clini- cal characteristics of multisystem inflammatory syn- drome in children (MIS-C) associated with covid-19 in critically ill patients: an observational multicentre study (MISCO study)	Lorena Acevedo et al. [25]	Colombia	Multicentric	Prospective and retro- spective	Median age: 7 years Sample size: 78 IMV: 27 Shock: 68	IVIG: 71 Steroids: 55 Antiplatelet drugs: 34 Anticoagulants: 34	AKI: 23 KRT: 9 Mortality: 7	Fair

Table 1 (continued)

S. no.	Study title	Study author	Country	Multicentric/ single centre	Prospective/retrospec- tive	Median age/sample size/invasive mechani- cal ventilation (IMV)/ shock	IVIg/steroids/anti- platelet/anticoagu- lants	AKI/KRT/mortality	Study quality (NHLBI tool)
23	Clinical features and outcomes of 76 patients with COVID-19-related multi-system inflammatory syndrome in children	Fatih Haslak et al. [26]	Turkey	Multicentric	Retrospective	Mean age: 8.17 years Sample size: 76 IMV: 3 Shock: not mentioned (18 patients received vasopressors)	IVIg: 27 Steroids: 26 Antiplatelet drugs: not mentioned Anticoagulants: 23	AKI: 8 KRT: 4 Mortality: 1	Good
24	Multisystem inflammatory syndrome in children—United States, February 2020–July 2021	Miller AD et al. [27]	USA	Multicentric	Retrospective	Median age: 9 years Sample size: 4470 IMV: 419 Shock: 2018	IVIg: 3772 Steroids: 3428 Antiplatelet drugs: not mentioned Anticoagulants: not mentioned	AKI: 849 KRT: 42 Mortality: 37	Fair

Abbreviations: AKI acute kidney injury, KRT kidney replacement therapy, IVIG intravenous immunoglobulin

patients in studies with large sample size [19% (95% CI: 18–20%)] was almost similar to incidence of AKI in studies with small sample size [21% (95% CI: 14–30%; $I^2 = 76\%$)] (Supplementary Fig. 4). Comparing incidence of AKI in MIS-C patients based on geography, we found that non-Asian studies had higher incidence of AKI [23% (95% CI: 14–35%; $I^2 = 90\%$)] as compared to Asian studies [18% (95% CI: 11–28%; $I^2 = 48\%$)] (Supplementary Fig. 5). The incidence of AKI was also higher in studies which used the KDIGO definition of AKI [24% (95% CI: 14–37%; $I^2 = 93\%$)] as compared to studies which used some other definition of AKI [18% (95% CI: 12–27%; $I^2 = 39\%$)] (Supplementary Fig. 6). There was a slightly higher proportion of children developing AKI in single-centre studies [23% (95% CI: 13–36%; $I^2 = 38\%$)] as compared to multicentric studies [20% (95% CI: 13–29%; $I^2 = 87\%$)] (Supplementary Fig. 7).

Mortality

All studies reported death in children with MIS-C. Pooled proportion of death in children with MIS-C was 4% (95% CI: 1–14%; $I^2 = 93\%$) (Fig. 3) (11 studies, 4947 patients). Due to unexplained heterogeneity in results, the Baujat plot was used, which identified studies (Miller AD, Gupta S) [27, 35] as outliers (Supplementary Fig. 8). However, on performing influential analysis, we could not find any study significantly contributing towards heterogeneity (Supplementary Fig. 9). Visual inspection of the funnel plot revealed asymmetry (Supplementary Fig. 10), but Egger’s test for publication bias was not significant ($p = 0.27$). Subgroup analysis of mortality was done based on sample size (large versus small), geography (Asian versus non-Asian studies), definition of AKI used (KDIGO versus others), and multicentric versus single-centre studies. The subgroup of smaller studies was compared with a single large study by Miller et al. and showed higher mortality in studies with smaller sample size [5% (95% CI: 2–15%; $I^2 = 83\%$)] than the study with larger sample size [1% (95% CI: 1–1%²)], and this result was significant (Supplementary Fig. 11). Mortality was also higher in Asian studies [7% (95% CI: 1–32%; $I^2 = 84\%$)] as compared to non-Asian studies [2% (95% CI: 1–7%; $I^2 = 88\%$)] (Supplementary Fig. 12). Mortality was less in studies which used KDIGO definition of AKI [2% (95% CI: 0–9%; $I^2 = 91\%$)] as compared to studies which used other definitions of AKI [6% (95% CI: 1–26%; $I^2 = 83\%$)] (Supplementary Fig. 13). The subgroup analysis based on multicentric versus single-centre study showed higher pooled mortality in multi-centre studies [2% (95% CI: 1–6%; $I^2 = 83\%$)] as compared to single-centre studies [12% (95% CI: 2–52%; $I^2 = 85\%$)] (Supplementary Fig. 14).

Risk of death in MIS-C patients with and without AKI

Four studies (Deep A, Acevedo L, Haslak F, Shobhavat L) [11, 25, 26, 33] provided data on AKI in deceased patients. The odds of death in patients with AKI were 4.68 times higher than in patients without AKI (95% CI: 1.06–20.7; $I^2 = 17%$) (Fig. 4).

Requirement of kidney replacement therapy

Five studies reported this outcome (Deep A, Garcia-Salido A, Acevedo L, Haslak F, Miller AD) [11, 18, 25–27]. The overall pooled proportion of MIS-C-induced AKI patients requiring KRT was 15% (95% CI: 4–42%; $I^2 = 91%$) (Fig. 5) (5 studies, 4785 patients). We used Baujat’s plot and identified a study (Miller AD) [27] as influencing the

Fig. 2 Pooled incidence of AKI in patients with MIS-C





Fig. 3 Overall mortality in patients with MIS-C



Study or Subgroup	AKI		Non AKI		Weight	Odds Ratio	M-H, Random, 95% CI
	Events	Total	Events	Total			
Deep A	2	48	0	68	20.3%	7.37	[0.35, 156.95]
Fatih Haslak	0	8	1	68	18.0%	2.65	[0.10, 70.29]
Lorena Acevedo	6	23	1	55	34.9%	19.06	[2.14, 169.62]
Shobhavat L	1	8	2	13	26.9%	0.79	[0.06, 10.38]
Total (95% CI)		87		204	100.0%	4.68	[1.06, 20.70]
Total events	9		4				
Heterogeneity: $\tau^2 = 0.41$; $\chi^2 = 3.63$, $df = 3$ ($P = 0.30$); $I^2 = 17%$							
Test for overall effect: $Z = 2.03$ ($P = 0.04$)							





Fig. 4 Comparison of death in MIS-C patients with and without AKI

Fig. 5 Pooled incidence of the need for kidney replacement therapy in patients with MIS-C



heterogeneity. However, influential analysis did not reveal significant heterogeneity (Supplementary Figs. 15 and 16).

Discussion

Our analysis found that one-fifth of the children with MIS-C develop AKI and have higher odds of death as compared to children with MIS-C without AKI. The incidence of AKI in pediatric patients is variable, ranging from 5 to 37% in ICU with variable requirement of KRT ranging from 20 to 23% [37, 38]. Thus, we see that patients with MIS-C have a similar risk of AKI when compared to pediatric patients in ICU due to other causes and their need for KRT may be slightly less (15%), as evident by our results. Our analysis of subgroups provided further insight into the incidence of AKI. We found that studies which used KDIGO criteria for diagnosis of AKI had higher incidence of AKI when compared to studies which used other criteria for AKI, which is in agreement with the previous literature.

Over the last decade, there has been a substantial change in the definition and staging of AKI. In the present review, out of 24 studies included for qualitative synthesis, only 21 used the term AKI. However, no definition was provided by 11 of these studies (Godfred-Cato S, Lima Setta F, Falah NU, Haslak F, Miller AD, Lee PY, Blumfield E, Sethuraman U, Cantor A, Shobhavat L, Dhanlakshmi K) [16, 17, 22, 26–29, 31–33, 39], 5 studies (Basalely A, Diorio C, Acevedo L, Lipton M, Capone CA) [10, 12, 25, 36, 40] used the KDIGO definition for AKI, while 4 studies used other definitions. Deep et al. used age-specific upper limit of reference values according to guidelines from the British Association of Pediatric Nephrology for AKI due to lack of previously known baseline creatinine values in their patients [11]. Garcia-Salido et al. defined AKI as serum creatinine values two times the upper normal reference for age and sex [18]. One study each used the terms ‘renal failure’, ‘prerenal insufficiency’, and ‘renal impairment’ (Moraleda C, Alkan G, Gupta S) [20, 34, 35].

The study by Miller et al. was the largest, including patients from all over the USA, and the study period encompassed all three waves of COVID-19. This study had 4470

cases of MIS-C, with 849 of them developing AKI, but only 42 of them required KRT. The study also provided data about AKI in each of the three waves, with 106 patients (of 649) developing AKI in the first wave, 166 patients (of 769) developing AKI in the second wave, and 577 patients (of 3052) developing AKI in the third wave. KRT was required in 5, 4, and 33 patients in each wave, respectively [27].

Godfred-cato et al. used latent class analysis to divide patients into three classes. Class 1 patients had the highest number of organ systems involved, while class 2 patients had predominantly respiratory involvement, and class 3 patients had manifestations most similar to Kawasaki disease. This report used the term AKI, but no definition was provided. Most patients with AKI (77 of 105) were in class 1, few were in class 2 (28 of 105), while no patient in class 3 developed AKI [16].

Deep et al. found that severe AKI in MIS-C was associated with nephrotoxic drugs, high BMI, and high ferritin values. However, on multivariate analysis, only association with hyperferritinemia was significant [11]. Basalely et al. also described the use of nephrotoxic drugs as a potential exacerbator of AKI in MIS-C [10]. The authors also found an association between a greater need for vasoactive medication and a longer duration of ICU stay among MIS-C patients who had AKI compared to those without AKI [10]. Similar findings were reported by Deep et al., who suggested that the duration of ICU stay and mechanical ventilation were longer in MIS-C patients who had severe AKI [11].

A peek into the mechanism of renal injury was provided by Diorio et al., who suggested a combination of viral infection of the cell along with complement activation and vascular injury as the cause. Elevations in sC5b9 were independent of other MIS-C markers and associated with renal injury [12].

Overall mortality in MIS-C patients in the present study was 4%. On subgroup analysis, we found that single-centre studies had slightly higher mortality rates than multicentric studies. Similarly, studies which used KDIGO definition had lower mortality when compared to studies that used other definitions of AKI, and Asian studies had higher mortality than non-Asian studies. However, none of these differences were significant. But we found significantly low mortality in

studies with larger sample size when compared with studies of smaller sample size. Mortality in PICU varies from 2 to 30% across countries based on availability of resources and common diseases leading to ICU admissions [41–44]. The present analysis also showed that mortality among MIS-C patients increases by 4.68 times if the patients develop AKI. Thus, mortality among MIS-C patients with AKI is comparable to mortality among PICU patients having AKI due to other causes. Previous studies in the pediatric age group have reported high mortality ranging from 11 to 36% in children with AKI [35, 37, 38, 45].

The strengths of this systematic review are as follows: (1) this is the first systematic review along with a meta-analysis describing incidence, mortality, and need for KRT in patients with MIS-C; and (2) the use of rigorous statistical methods to explore the heterogeneity among included studies.

A possible limitation can be considered because of different definitions of AKI being used in different studies. Also, not all studies provided data about the cause of death, and as such, mortality specific to AKI in MIS-C could vary if these data are included. Another limitation that should be considered is the heterogeneous ways the different retrospective studies were performed. Lack of prospective data is another limitation of this systematic review.

Conclusion

Approximately 20% of children with MIS-C develop AKI which is associated with higher odds of death.

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1007/s00467-022-05701-3>.

Acknowledgements The authors would like to thank Mr Amit Gupta, senior librarian, AIIMS Bhopal, for helping in search strategy and providing full text of articles.

Author contribution GCB and RP conceptualized the review; AT, AK, MA, and RP extracted the data from the studies and wrote the initial draft of the manuscript; GCB performed statistical analysis; GCB and SM revised the manuscript and contrived the final draft. All authors read and approved the final version of the manuscript.

Declarations

Conflict of interest The authors declare no competing interests.

References

- Rowley AH (2020) Understanding SARS-CoV-2-related multisystem inflammatory syndrome in children. *Nat Rev Immunol* 20:453–454. <https://doi.org/10.1038/s41577-020-0367-5>
- Kabeerdoss J, Pilonia RK, Karkhele R, Kumar TS, Danda D, Singh S (2021) Severe COVID-19, multisystem inflammatory syndrome in children, and Kawasaki disease: immunological mechanisms, clinical manifestations and management. *Rheumatol Int* 41:19–32. <https://doi.org/10.1007/s00296-020-04749-4>
- Payne AB, Gilani Z, Godfred-Cato S, Belay ED et al (2021) Incidence of multisystem inflammatory syndrome in children among US persons infected with SARS-CoV-2. *JAMA Netw Open* 4:e2116420. <https://doi.org/10.1001/jamanetworkopen.2021.16420>
- (2021) HAN Archive - 00432 | Health Alert Network (HAN). <https://emergency.cdc.gov/han/2020/han00432.asp>. Accessed 14 Nov 2021
- Multisystem inflammatory syndrome in children and adolescents with COVID-19. <https://www.who.int/publications-detail-redirect/multisystem-inflammatory-syndrome-in-children-and-adolescents-with-covid-19>. Accessed 14 Nov 2021
- (2020) Rapid risk assessment: Paediatric inflammatory multisystem syndrome and SARS-CoV-2 infection in children. In: European Centre for Disease Prevention and Control. <https://www.ecdc.europa.eu/en/publications-data/paediatric-inflammatory-multisystem-syndrome-and-sars-cov-2-rapid-risk-assessment>. Accessed 14 Nov 2021
- Fabi M, Filice E, Biagi C, Andreozzi L, Palleri D, Mattesini BE, Rizzello A, Gabrielli L, Ghizzi C, Di Luca D, Caramelli F, De Fanti A, Lanari M (2021) Multisystem inflammatory syndrome following SARS-CoV-2 infection in children: one year after the onset of the pandemic in a high-incidence area. *Viruses* 13:2022. <https://doi.org/10.3390/v13102022>
- Jiang L, Tang K, Levin M, Irfan O, Morris SK, Wilson K, Klein JD, Bhutta ZA (2020) COVID-19 and multisystem inflammatory syndrome in children and adolescents. *Lancet Infect Dis* 20:e276–e288. [https://doi.org/10.1016/S1473-3099\(20\)30651-4](https://doi.org/10.1016/S1473-3099(20)30651-4)
- Irfan O, Muttalib F, Tang K, Jiang L, Lassi ZS, Bhutta Z (2021) Clinical characteristics, treatment and outcomes of paediatric COVID-19: a systematic review and meta-analysis. *Arch Dis Child* 106:440–448. <https://doi.org/10.1136/archdischild-2020-321385>
- Basalely A, Gurusinghe S, Schneider J, Shah SS, Siegel LB, Pollack G, Singer P, Castellanos-Reyes LJ, Fishbane S, Jhaveri KD, Mitchell E, Merchant K, Capone C, Gefen AM, Steinberg J, Sethna CB (2021) Acute kidney injury in pediatric patients hospitalized with acute COVID-19 and multisystem inflammatory syndrome in children associated with COVID-19. *Kidney Int* 100:138–145. <https://doi.org/10.1016/j.kint.2021.02.026>
- Deep A, Upadhyay G, du Pré P, Lillie J et al (2020) Acute kidney injury in pediatric inflammatory multisystem syndrome temporally associated with severe acute respiratory syndrome coronavirus-2 pandemic: experience from PICUs across United Kingdom. *Crit Care Med* 48:1809–1818. <https://doi.org/10.1097/CCM.0000000000004662>
- Diorio C, McNerney KO, Lambert M, Paessler M et al (2020) Evidence of thrombotic microangiopathy in children with SARS-CoV-2 across the spectrum of clinical presentations. *Blood Adv* 4:6051–6063. <https://doi.org/10.1182/bloodadvances.2020003471>
- Pilonia RK, Dokania S, Kumar A, Ahmad R, Malik S, Bhatt GC (2021) Acute renal failure requiring renal replacement therapy: unusual presentation of multisystem inflammatory syndrome in children. *J Paediatr Child Health* 57:1724–1725. <https://doi.org/10.1111/jpc.15715>
- Higgins JPT, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. *BMJ* 327:557–560
- Viechtbauer W, Cheung MW-L (2010) Outlier and influence diagnostics for meta-analysis. *Res Synth Methods* 1:112–125. <https://doi.org/10.1002/jrsm.11>
- Godfred-Cato S, Bryant B, Leung J, Oster ME et al (2020) COVID-19-associated multisystem inflammatory syndrome in

- children — United States, March–July 2020. *MMWR Morb Mortal Wkly Rep* 69:1074–1080
17. Lima-Setta F, de Magalhães-Barbosa MC, Rodrigues-Santos G, Figueiredo EADN et al (2021) Multisystem inflammatory syndrome in children (MIS-C) during SARS-CoV-2 pandemic in Brazil: a multicenter, prospective cohort study. *J Pediatr (Rio J)* 97:354–361. <https://doi.org/10.1016/j.jpeds.2020.10.008>
 18. García-Salido A, de Carlos Vicente JC, Belda Hofheinz S, Balcells Ramírez J et al (2020) Severe manifestations of SARS-CoV-2 in children and adolescents: from COVID-19 pneumonia to multisystem inflammatory syndrome: a multicentre study in pediatric intensive care units in Spain. *Crit Care* 24:666. <https://doi.org/10.1186/s13054-020-03332-4>
 19. Davies P, Evans C, Kanthimathinathan HK, Lillie J et al (2020) Intensive care admissions of children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS) in the UK: a multicentre observational study. *Lancet Child Adolesc Health* 4:669–677. [https://doi.org/10.1016/S2352-4642\(20\)30215-7](https://doi.org/10.1016/S2352-4642(20)30215-7)
 20. Moraleda C, Serna-Pascual M, Soriano-Arandes A, Simó S et al (2021) Multi-inflammatory syndrome in children related to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Spain. *Clin Infect Dis* 72:e397–e401. <https://doi.org/10.1093/cid/ciaa1042>
 21. Capone CA, Subramony A, Sweberg T, Schneider J et al (2020) Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 infection. *J Pediatr* 224:141–145. <https://doi.org/10.1016/j.jpeds.2020.06.044>
 22. Falah NU, Hashmi S, Ahmed Z, Jaan A, Akhtar A, Khalid F, Farooque U, Shera MT, Ali S, Javed A (2020) Kawasaki disease-like features in 10 pediatric COVID-19 cases: a retrospective study. *Cureus* 12:e11035. <https://doi.org/10.7759/cureus.11035>
 23. Feldstein LR, Rose EB, Horwitz SM, Collins JP et al (2020) Multisystem inflammatory syndrome in U.S. children and adolescents. *N Engl J Med* 383:334–346. <https://doi.org/10.1056/NEJMoa2021680>
 24. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM et al (2020) Multisystem inflammatory syndrome in children in New York State. *N Engl J Med* 383:347–358. <https://doi.org/10.1056/NEJMoa2021756>
 25. Acevedo L, Piñeres-Olave BE, Niño-Serna LF, Vega LM et al (2021) Mortality and clinical characteristics of multisystem inflammatory syndrome in children (MIS-C) associated with covid-19 in critically ill patients: an observational multicenter study (MISCO study). *BMC Pediatr* 21:516. <https://doi.org/10.1186/s12887-021-02974-9>
 26. Haslak F, Barut K, Durak C, Aliyeva A et al (2021) Clinical features and outcomes of 76 patients with COVID-19-related multisystem inflammatory syndrome in children. *Clin Rheumatol* 40:4167–4178. <https://doi.org/10.1007/s10067-021-05780-x>
 27. Miller AD, Zambrano LD, Yousaf AR, Abrams JY, Meng L, Wu MJ, Melgar M, Oster ME, Godfred Cato SE, Belay ED, Campbell AP; MIS-C Surveillance Authorship Group (2021) Multisystem inflammatory syndrome in children—United States, February 2020–July 2021. *Clin Infect Dis*. <https://doi.org/10.1093/cid/ciab1007>
 28. Lee PY, Day-Lewis M, Henderson LA, Friedman KG et al (2020) Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children. *J Clin Invest* 130:5942–5950. <https://doi.org/10.1172/JCI141113>
 29. Blumfield E, Levin TL, Kurian J, Lee EY, Liszewski MC (2021) Imaging findings in multisystem inflammatory syndrome in children (MIS-C) associated with coronavirus disease (COVID-19). *AJR Am J Roentgenol* 216:507–517. <https://doi.org/10.2214/AJR.20.24032>
 30. Dhanalakshmi K, Venkataraman A, Balasubramanian S, Madhusudan M, Amperayani S, Putlibai S, Sadasivam K, Ramachandran B, Ramanan AV (2020) Epidemiological and clinical profile of pediatric inflammatory multisystem syndrome — temporally associated with SARS-CoV-2 (PIMS-TS) in Indian Children. *Indian Pediatr* 57:1010–1014
 31. Sethuraman U, Kannikeswaran N, Ang J, Singer A, Miller J, Haddad R, Stankovic C (2021) Multisystem inflammatory syndrome in children associated with novel coronavirus SARS-CoV-2: presentations to a pediatric emergency department in Michigan. *Am J Emerg Med* 39:164–167. <https://doi.org/10.1016/j.ajem.2020.10.035>
 32. Cantor A, Miller J, Zachariah P, DaSilva B, Margolis K, Martinez M (2020) Acute hepatitis is a prominent presentation of the multisystem inflammatory syndrome in children: a single-center report. *Hepatology* 72:1522–1527. <https://doi.org/10.1002/hep.31526>
 33. Shobhavat L, Solomon R, Rao S, Bhagat I, Prabhu S, Prabhu S, Chandrakar M, Bodhanwala M (2020) Multisystem inflammatory syndrome in children: clinical features and management-intensive care experience from a pediatric public hospital in Western India. *Indian J Crit Care Med* 24:1089–1094. <https://doi.org/10.5005/jp-journals-10071-23658>
 34. Alkan G, Sert A, Oz SKT, Emiroglu M, Yılmaz R (2021) Clinical features and outcome of MIS-C patients: an experience from Central Anatolia. *Clin Rheumatol* 40:4179–4189. <https://doi.org/10.1007/s10067-021-05754-z>
 35. Gupta S, Chopra N, Singh A, Gera R, Chellani H, Pandey R, Arora BS (2021) Unusual clinical manifestations and outcome of multisystem inflammatory syndrome in children (MIS-C) in a tertiary care hospital of North India. *J Trop Pediatr* 67:fmaa127. <https://doi.org/10.1093/tropej/fmaa127>
 36. Lipton M, Mahajan R, Kavanagh C, Shen C, Batal I, Dogra S, Jain NG, Lin F, Uy NS (2021) AKI in COVID-19-associated multisystem inflammatory syndrome in children (MIS-C). *Kidney* 360:611–618. <https://doi.org/10.34067/KID.0005372020>
 37. Bouchard J, Acharya A, Cerda J, Maccariello ER, Madarasu RC, Tolwani AJ, Liang X, Fu P, Liu ZH, Mehta RL (2015) A prospective international multicenter study of AKI in the intensive care unit. *Clin J Am Soc Nephrol* 10:1324–1331. <https://doi.org/10.2215/CJN.04360514>
 38. Restrepo JM, Mondragon MV, Forero-Delgado JM, Lasso RE, Zemanate E, Bravo Y, Castillo GE, Tetay S, Cabal N, Calvache JA (2020) Acute renal failure in children. Multicenter prospective cohort study in medium-complexity intensive care units from the Colombian southeast. *PLoS One* 15:e0235976. <https://doi.org/10.1371/journal.pone.0235976>
 39. Dhanalakshmi K, Venkataraman A, Balasubramanian S, Madhusudan M, Amperayani S, Putlibai S, Sadasivam K, Ramachandran B, Ramanan AV (2020) Epidemiological and clinical profile of pediatric inflammatory multisystem syndrome — temporally associated with SARS-CoV-2 (PIMS-TS) in Indian Children. *Indian Pediatr* 57:1010–1014
 40. Capone CA, Subramony A, Sweberg T, Schneider J, Shah S, Rubin L, Schleien C, Northwell Health COVID-19 Research Consortium, Epstein S, Johnson JC, Kessel A, Misra N, Mitchell E, Palumbo N, Rajan S, Rucker J, Williamson K, Davidson KW (2020) Characteristics, cardiac involvement, and outcomes of multisystem inflammatory syndrome of childhood associated with severe acute respiratory syndrome coronavirus 2 Infection. *J Pediatr* 224:141–145. <https://doi.org/10.1016/j.jpeds.2020.06.044>
 41. Teshager NW, Amare AT, Tamirat KS (2020) Incidence and predictors of mortality among children admitted to the pediatric intensive care unit at the University of Gondar comprehensive specialised hospital, northwest Ethiopia: a prospective observational cohort study. *BMJ Open* 10:e036746. <https://doi.org/10.1136/bmjopen-2019-036746>

42. Punchak M, Hall K, Seni A, Buck WC, DeUgarte DA, Hartford E, Kelly RB, Muando VI (2018) Epidemiology of disease and mortality from a PICU in Mozambique. *Pediatr Crit Care Med* 19:e603–e610. <https://doi.org/10.1097/PCC.0000000000001705>
43. Burns JP, Sellers DE, Meyer EC, Lewis-Newby M, Truog RD (2014) Epidemiology of death in the pediatric intensive care unit at five U.S. teaching hospitals. *Crit Care Med* 42:2101–2108. <https://doi.org/10.1097/CCM.0000000000000498>
44. Siddiqui N-R, Ashraf Z, Jurair H, Haque A (2015) Mortality patterns among critically ill children in a pediatric intensive care unit of a developing country. *Indian J Crit Care Med* 19:147–150. <https://doi.org/10.4103/0972-5229.152756>
45. Safder OY, Alhasan KA, Shalaby MA, Khathlan N, Al Rezgan SA, Albanna AS, Kari JA (2019) Short-term outcome associated

with disease severity and electrolyte abnormalities among critically ill children with acute kidney injury. *BMC Nephrol* 20:89. <https://doi.org/10.1186/s12882-019-1278-1>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.